References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394–424.
- Mokhatri-Hesari P, Montazeri A: Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes 2020, 18(1):338.
- Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS et al: How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology 2017, 28(9):2077–2085.
- Velikova G, Coens C, Efficace F, Greimel E, Groenvold M, Johnson C, Singer S, van de Poll-Franse L, Young T, Bottomley A: Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice. European Journal of Cancer Supplements 2012, 10(1):141–149.
- EORTC. EORTC QLQ-C30 (Version 3). EORTC Study Group on Quality of Life. 1995 [
https://qol.eortc.org/ ] - EORTC. EORTC QLQ-BR23. (version 1). EORTC Study Group on Quality of Life. 1994 [
https://qol.eortc.org/ ] - Perez EA: Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Annals of Oncology 2007, 18:viii26–viii35.
- van Nes JGH, Fontein DBY, Hille ETM, Voskuil DW, van Leeuwen FE, de Haes JCJM, Putter H, Seynaeve C, Nortier JWR, van de Velde CJH: Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Research and Treatment 2012, 134(1):267–276.
- Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology 2011, 12(3):236–244.
- Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, Loi S, Verma S, Iwata H, Bhattacharyya H et al: Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of Oncology 2016, 27(6):1047–1054.
- Winters ZE, Afzal M, Rutherford C, Holzner B, Rumpold G, da Costa Vieira RA, Hartup S, Flitcroft K, Bjelic-Radisic V, Oberguggenberger A et al: International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction. British Journal of Surgery 2018, 105(3):209–222.
- Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M et al: An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Annals of oncology : official journal of the European Society for Medical Oncology 2020, 31(2):283–288.
- Raosoft sample size calculator [
http://www.raosoft.com/samplesize.html ] - EORTC. EORTC Scoring Manual (Third Edition). 2001 [
https://www.eortc.org/ ] - Eortc Quality Of Life Group Translation Procedure, Fourth edition [
https://www.eortc.org/app/uploads/sites/2/2018/02/translation_manual_2017.pdf ] - Beaton DE, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000, 25(24):3186–3191.
- Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P et al: The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996, 14(10):2756–2768.
- Cronbach LJJp: Coefficient alpha and the internal structure of tests. 1951, 16(3):297–334.
- El Fakir S, Abda N, Bendahhou K, Zidouh A, Bennani M, Errihani H, Benider A, Bekkali R, Nejjari C: The European Organization for Research and Treatment of Cancer quality of life questionnaire-BR23 Breast Cancer-Specific Quality of Life Questionnaire: psychometric properties in a Moroccan sample of breast cancer patients. BMC research notes 2014, 7:53.
- Gadisa DA, Gebremariam ET, Ali GY: Reliability and validity of Amharic version of EORTC QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among breast cancer patients in Ethiopia. Health Qual Life Outcomes 2019, 17(1):182.
- Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M, Haji-Mahmoodi M: The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2000, 9(2):177–184.
- Cerezo O, Oñate-Ocaña LF, Arrieta-Joffe P, González-Lara F, García-Pasquel MJ, Bargalló-Rocha E, Vilar-Compte D: Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer. European journal of cancer care 2012, 21(5):684–691.
- Demirci S, Eser E, Ozsaran Z, Tankisi D, Aras AB, Ozaydemir G, Anacak Y: Validation of the Turkish versions of EORTC QLQ-C30 and BR23 modules in breast cancer patients. Asian Pac J Cancer Prev 2011, 12(5):1283–1287.
- Chie WC, Chang KJ, Huang CS, Kuo WH: Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology 2003, 12(7):729–735.
- Awad MA, Denic S, El Taji H: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires for Arabic-speaking Populations. Annals of the New York Academy of Sciences 2008, 1138:146–154.
- Roshandel S, Lamyian M, Azin SA, Haghighat S, Mohammadi E: Development and validation of a guideline on sexual and reproductive health of breast cancer survivors in Iran: a mixed methods study protocol. Health Research Policy and Systems 2021, 19(1):87.
- Mikiyas Amare G, Panpan W, Eva Johanna K, Edom S, Changying C, Adamu A: Health Qual Life Outcomes 2021.
- Brédart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C: Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients’ experience. Health Qual Life Outcomes 2014, 12:15–15.